Real-World Outcomes of Chemoradiotherapy in Patients with Stage II/III Non-Small-Cell Lung Cancer in the Durvalumab Era: An Observational Study.

Cancers (Basel) · 2025 · PMC12345666 · PMID 40805195

Europe PMC DOI

hedged sentences

0.0630

closest p · 1.3× alpha

0.3000

boldest claim

The sentences

showed a trendp = 0.063so close (0.05 < p ≤ 0.1)

PD-L1 expression ≥ 1% showed a trend toward improved OS (HR 3.72, p = 0.063).

also in 53,322 other papers

borderline significancep = 0.093so close (0.05 < p ≤ 0.1)

Nodal stage showed borderline significance ( p = 0.093), while T-stage and age remained non-significant in the final model.

also in 7,017 other papers

a nonsignificant trendp = 0.3not close (p > 0.1)

In the univariate model, Karnofsky performance status > 80% was associated with a significantly better PFS (HR 0.37, 95% CI 0.19–0.76, p = 0.003), and CCI ≤ 2 showed a nonsignificant trend toward improved outcomes (HR 0.73, 95% CI 0.40–1.34, p = 0.3).

also in 5,406 other papers

did not reach statistical significanceno p-value reported

Female sex also showed a trend toward better survival (HR 0.48, 95% CI 0.21–1.06, p = 0.049), while other variables such as age at diagnosis, CCI group, T-stage, N-stage, PD-L1 status, and durvalumab treatment did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.